Imugene (Australia) Buy Hold or Sell Recommendation
| IMU Stock | 0.04 0 5.26% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Imugene is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Imugene given historical horizon and risk tolerance towards Imugene. When Macroaxis issues a 'buy' or 'sell' recommendation for Imugene, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Imugene Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Imugene and provide practical buy, sell, or hold advice based on investors' constraints. Imugene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Imugene |
Execute Imugene Buy or Sell Advice
The Imugene recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Imugene. Macroaxis does not own or have any residual interests in Imugene or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Imugene's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Imugene Trading Alerts and Improvement Suggestions
| Imugene generated a negative expected return over the last 90 days | |
| Imugene has some characteristics of a very speculative penny stock | |
| Imugene has high historical volatility and very poor performance | |
| Imugene has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 4.97 M. Net Loss for the year was (149.68 M) with profit before overhead, payroll, taxes, and interest of 11.78 M. | |
| Imugene has accumulated about 49.54 M in cash with (97.32 M) of positive cash flow from operations. | |
| Roughly 14.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: ASX Health Stocks Imugene reveals promise in lymphoma trial, stock soars 27pc - MSN |
Imugene current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Imugene analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Imugene analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Imugene Returns Distribution Density
The distribution of Imugene's historical returns is an attempt to chart the uncertainty of Imugene's future price movements. The chart of the probability distribution of Imugene daily returns describes the distribution of returns around its average expected value. We use Imugene price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Imugene returns is essential to provide solid investment advice for Imugene.
| Mean Return | -0.39 | Value At Risk | -7.55 | Potential Upside | 6.82 | Standard Deviation | 4.08 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Imugene historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Imugene Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 11.1M | (619.7K) | 70.4M | 53.3M | (60.0M) | (57.0M) | |
| Free Cash Flow | (11.6M) | (18.6M) | (30.9M) | (29.8M) | (106.8M) | (101.4M) | |
| Depreciation | 82.5K | 2.0M | 2.4M | 2.2M | 5.8M | 6.1M | |
| Other Non Cash Items | 2.5M | 12.1M | 17.1M | 10.2M | 52.4M | 55.0M | |
| Capital Expenditures | 128.4K | 1.5M | 5.4M | 257.7K | 13.1M | 13.7M | |
| Net Income | (10.5M) | (18.5M) | (37.9M) | (37.9M) | (149.7M) | (142.2M) | |
| End Period Cash Flow | 30.1M | 29.5M | 99.9M | 153.2M | 93.1M | 97.8M | |
| Change To Inventory | 987.1K | (51.5K) | (1.9M) | 676.9K | 609.2K | 639.7K | |
| Investments | (30.6K) | (34.6K) | (137.2K) | 1.9M | (7.3M) | (6.9M) | |
| Net Borrowings | (53.6K) | 67.9K | (10.8K) | (147.4K) | (132.7K) | (126.0K) | |
| Change To Netincome | 1.0M | 5.6M | 8.8M | 3.6M | 4.2M | 4.4M |
Imugene Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Imugene or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Imugene's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Imugene stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.41 | |
β | Beta against Dow Jones | 0.07 | |
σ | Overall volatility | 3.92 | |
Ir | Information ratio | -0.13 |
Imugene Volatility Alert
Imugene exhibits very low volatility with skewness of 0.19 and kurtosis of 0.19. Imugene is a penny stock. Although Imugene may be in fact a good investment, many penny stocks are subject to artificial price hype. Make sure you completely understand the upside potential and downside risk of investing in Imugene. We encourage investors to look for signals such as message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on Imugene instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Imugene Fundamentals Vs Peers
Comparing Imugene's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Imugene's direct or indirect competition across all of the common fundamentals between Imugene and the related equities. This way, we can detect undervalued stocks with similar characteristics as Imugene or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Imugene's fundamental indicators could also be used in its relative valuation, which is a method of valuing Imugene by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Imugene to competition |
| Fundamentals | Imugene | Peer Average |
| Return On Equity | -0.97 | -0.31 |
| Return On Asset | -0.51 | -0.14 |
| Operating Margin | 22.86 % | (5.51) % |
| Current Valuation | 195.99 M | 16.62 B |
| Shares Outstanding | 7.57 B | 571.82 M |
| Shares Owned By Insiders | 14.38 % | 10.09 % |
| Shares Owned By Institutions | 6.60 % | 39.21 % |
| Price To Book | 2.43 X | 9.51 X |
| Price To Sales | 60.90 X | 11.42 X |
| Revenue | 4.97 M | 9.43 B |
| Gross Profit | 11.78 M | 27.38 B |
| EBITDA | (147.98 M) | 3.9 B |
| Net Income | (149.68 M) | 570.98 M |
| Cash And Equivalents | 49.54 M | 2.7 B |
| Total Debt | 1.55 M | 5.32 B |
| Book Value Per Share | 0.02 X | 1.93 K |
| Cash Flow From Operations | (97.32 M) | 971.22 M |
| Earnings Per Share | (0.02) X | 3.12 X |
| Target Price | 0.3 | |
| Beta | 3.34 | -0.15 |
| Market Capitalization | 302.68 M | 19.03 B |
| Total Asset | 151.4 M | 29.47 B |
| Retained Earnings | (289.83 M) | 9.33 B |
| Working Capital | 83.74 M | 1.48 B |
| Net Asset | 151.4 M |
Imugene Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Imugene . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Imugene Buy or Sell Advice
When is the right time to buy or sell Imugene? Buying financial instruments such as Imugene Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Imugene in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Convertibles Funds Thematic Idea Now
Convertibles Funds
Funds or Etfs that invest in debt that is expected to be converted into a predetermined amount of the company equity at some future date. The Convertibles Funds theme has 12 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Convertibles Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.